US Post News
  • Home
  • Stocks Trading
  • Analyst Snapshot
  • Market Summary
  • Financial Scores
No Result
View All Result
  • Home
  • Stocks Trading
  • Analyst Snapshot
  • Market Summary
  • Financial Scores
No Result
View All Result
US Post News
No Result
View All Result

Do you want to know where to find good stock? Take a look at Ascendis Pharma A/S’s (NASDAQ:ASND) Sentiment Analysis

July 27, 2022
in Market Summary

Ascendis Pharma A/S (ASND)’s stock has witnessed a price hike of 0.63% from the previous close with its current price standing at $87.57. Its current price is -51.00% under its 52-week high of $178.71 and 42.21% more than its 52-week low of $61.58. Based on the past 30-day period, the stock price is -8.59% below the high and +5.89% above the low.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.

Sponsored

The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, ASND’s SMA-200 is $116.26.

Additionally, you should consider the price-to-sales ratio a company has had for the past year, which is 324.07 right now. ASND’s price to book ratio for the most recent quarter was 7.22, resulting in an 4.60 price to cash per share for the period.

How does Ascendis Pharma A/S (ASND) stock rate among analysts? Buy, sell, or hold?

The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 10 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.70 in simple terms.

Ascendis Pharma A/S (ASND): Earnings History

If we examine Ascendis Pharma A/S’s recent earnings history, in the last quarter ended on 3/30/2022, it posted adjusted earnings per share of -$2.25, beating the consensus of -$2.04. In other words, it beat the consensus by -$0.21, resulting in a -10.30% surprise. In the 3 months period before the previous quarter which was closed on 3/30/2022, the stock recorded adjusted earnings per share of -$2.25 in contrast with the Outlook of -$2.04. That was a difference of -$0.21 and a surprise of -10.30%.

Ascendis Pharma A/S (ASND): Earnings History

Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 7 different analysts, who are expecting earnings to fall in between the range of -0.99 and -2.42 with an average Earnings Estimate of -2.11 which is in contrast with the last year earnings estimate of -3.01 and also replicates 29.90% growth rate year over year.

Ascendis Pharma A/S (NASDAQ: ASND) Ownership Details

I will give a breakdown of the key shareholders in Ascendis Pharma A/S (ASND). Recent figures show that the company’s insiders hold 0.07% of shares. A total of 238 institutional investors hold shares in the company, making 127.13% of its stock and 127.21% of its float.

Mar 30, 2022, it was reported that the Company’s largest institutional holder is Artisan Partners Limited Partnership holding total of 8.21 million shares that make 14.42% of the company’s total number of shares and are currently priced at 719.21 million.

The securities firm RA Capital Management, L.P. holds 7.57 million shares of ASND, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 13.29%, and the holding percentage of shares is valued at 662.72 million.

An overview of Ascendis Pharma A/S’s technicals

>> 5 Best Inflation Stocks for 2022 <<

>> 5 Best Inflation Stocks for 2022 <<

In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Ascendis Pharma A/S (ASND) traded 323,305 shares per day, with a moving average of $90.13 and price change of -7.53. With the moving average of $88.34 and a price change of +7.56, about 395,056 shares changed hands on average over the past 50 days. Finally, ASND’s 100-day average volume is 511,089 shares, alongside a moving average of $97.15 and a price change of -18.91.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

BSMX (Banco Santander Mexico SA ADR) has powerful results

February 20, 2023

There Are Mixed Signals on the Chart for Gran Tierra Energy Inc. (GTE)

February 22, 2023

This morning’s top pick is New Gold Inc. (AMEX:NGD)

March 28, 2023

“US Post News” – one of the oldest and most authoritative news sites in America. It was established in 1992, journalists, photographers, correspondents, researchers came to the publication from the editorial offices of regional newspapers, drama theater, etc. They had no training, and they gained experience and skill in the process of work.

Contact us: ceo@www.uspostnews.com

Catagories

  • Market Summary
  • Stocks Trading
  • Analyst Snapshot
  • Financial Scores

Company

  • Home
  • About US
  • Contact US

RECENT POSTS

  • The Battle of Fundamentals and Techniques: Antero Resources Corporation (AR)
  • There Are Mixed Signals on the Chart for UP Fintech Holding Limited (TIGR)
  • Introducing Our Rant Against Intra-Cellular Therapies Inc.

Copyright © 2022 US Post News

No Result
View All Result
  • About US
  • Contact US
  • Home

Copyright © 2022 US Post News